Status:
UNKNOWN
Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS
Lead Sponsor:
Beijing Anzhen Hospital
Conditions:
Acute Coronary Syndrome
Angioplasty
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Rosuvastatin reload may prevent myocardial damage in ACS patients undergoing PCI
Eligibility Criteria
Inclusion
- 18-75 year old
- diagnosed as acute coronary syndrome
- Plan to PCI
Exclusion
- STEMI patient
- emergency PCI(\<2h) for NSTE-ACS
- History of liver disease and myopathy (ALT/AST\>3 x upper limit of normal,CK\>5 x upper limit of normal)
- TG\>500mg/dl,CCr\<30ml/min
- inflammatory disease
- allergic to rosuvastatin
- nephrotic syndrome,hypothyroidism,systemic lupus erythematosus,myeloma,et.al.
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2011
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT01245803
Start Date
April 1 2010
End Date
May 1 2011
Last Update
November 23 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the 28th division, Beijing Anzhen Hospital
Beijing, Beijing Municipality, China, 100029